Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety and effectiveness of daclatasvir-based regimens in Chinese chronic hepatitis C
CTR20181517Phase 4Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of daclatasvir, asunaprevir in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Started Sep 2018; status: terminated.
02
Drugs
daclatasvirasunaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20181517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181517.